4802 T3D4747 Cyproterone acetate An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. 427-51-0 9880 C24H29ClO4 White powder. 200-201°C Completely absorbed following oral administration. The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone. Primarily hepatic. Cyproterone acetate is metabolized by the CYP3A4 enzyme, forming the active metabolite 15beta-hydroxycyproterone acetate, which retains its antiandrogen activity, but has reduced progestational activity. Route of Elimination: It is excreted approximately 60% in the bile and 33% through the kidneys. Half Life: Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively. No indication of carcinogenicity to humans (not listed by IARC). For the palliative treatment of patients with advanced prostatic carcinoma. 2014-09-11T05:14:37Z 2026-03-26T21:34:31Z Cyproterone_acetate 50743 DB04839 true [H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H] C24H29ClO4 InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1 UWFYSQMTEOIJJG-FDTZYFLXSA-N 416.938 416.175437123 Exogenous Solid CHEMBL142130 9496 <p>Aranya Manosroi, &#8220;Synthesis of cyproterone acetate.&#8221; U.S. Patent US20040024230, issued February 05, 2004.</p> CHEM003704 DTXSID5020366 NS00003744 (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadeca-7,9-dien-15-yl acetate